Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Phase 2b CTR20231695

Phase 2b CTR20231695

Bofanglutide (GZR18) · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Bofanglutide (GZR18)
Population
obesity
Phase
2
Participants
64
Duration
30 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
12 mg Q2Wobesity china3052——−11.2 % vs −1.0 %
estimand not specified
—————0.0—press release
18 mg Q2Wobesity china3053——−13.2 % vs −1.0 %
estimand not specified
—————0.0—press release
24 mg Q2Wobesity china3052——−14.2 % vs −1.0 %
estimand not specified
—————0.0—press release
48 mg Q2Wobesity china3064——−17.3 % vs −1.0 %
estimand not specified
—————0.0—press release
24 mg QWobesity china3053——−17.8 % vs −1.0 %
estimand not specified
—————0.0—press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (10)
  • 12 mg Q2W · weight_unsp · press release
    11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
  • 12 mg Q2W · sae · press release, safety paragraph
    No serious adverse events were reported in any treatment group.
  • 18 mg Q2W · weight_unsp · press release
    11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
  • 18 mg Q2W · sae · press release, safety paragraph
    No serious adverse events were reported in any treatment group.
  • 24 mg Q2W · weight_unsp · press release
    11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
  • 24 mg Q2W · sae · press release, safety paragraph
    No serious adverse events were reported in any treatment group.
  • 48 mg Q2W · weight_unsp · press release
    11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
  • 48 mg Q2W · sae · press release, safety paragraph
    No serious adverse events were reported in any treatment group.
  • 24 mg QW · weight_unsp · press release
    In the QW 24 mg group, participants experienced a weight reduction of 17.78% (1.01)
  • 24 mg QW · sae · press release, safety paragraph
    No serious adverse events were reported in any treatment group.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Phase 2b CTR20231695. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-2b-ctr20231695/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.